Oncopeptides AB develops chemotherapeutic pharmaceuticals of compounds for cancer treatment. It enhances oncology therapies that target multiple myeloma by using existing basic cytotoxic compounds. The firm's compound, named melflufen, is a chemotherapeutic alkylator melphalan.
STOCKHOLM (Nyhetsbyrån Direkt) Industrifonden har sålt 3 miljoner aktier i Oncopeptides till institutionella investerare. Posten motsvarar 5,4
Oncopeptides största ägare, Industrifonden, har anlitat Jefferies för att sälja upp till 1,2 miljoner. STOCKHOLM (Fonder Direkt) Industrifonden har minskat sitt aktieinnehav i forskningsbolaget Oncopeptides till 13,4 procent av kapitalet och Forskningsbolaget Oncopeptides backar i spåren av att Industrifonden sålt tre miljoner aktier. Efter 90 minuters handel var OMXS30-indexet ned 0,27 procent. STOCKHOLM (Nyhetsbyrån Direkt) Industrifonden har sålt 3 miljoner aktier i Oncopeptides till institutionella investerare.
Feb 25, 2021 The big shareholder groups in Oncopeptides AB (publ) ( STO:ONCO ) have Industrifonden is the second largest shareholder owning 11% of Oncopeptides operates from the headquarters in Stockholm and is listed in the Mid Cap segment on Nasdaq Stockholm with the ticker ONCO. Industrifonden is Industrifonden is a Nordic venture capital investor, focusing on early stage 14 companies, among those AMRA, BONESUPPORT and Oncopeptides. Innogest Oct 21, 2020 Nomination committee in Oncopeptides established HealthCap VI L.P.; Patrik Sobocki, appointed by Stiftelsen Industrifonden; Ulrik Grönvall, NOTERA: Dessa sidor är för närvarande under uppbyggnad, och kommer inom kort innehålla mycket mer information om Oncopeptides: bolagsinformation, 2019年11月22日 本轮融资由Industrifonden和NordicNinja VC牵头。 Your Brand、Fishbrain和 生命科学公司CellaVision、Oncopeptides和AMRA。 >>>>. Feb 18, 2021 Karolinska Development was among the first to invest in the company, with others such as Industrifonden following suit later.
Industrifonden sålde 3 miljoner Oncopeptides-aktier under gårdagen för 107,5 kronor styck. Aktien stängde på 117 kronor, vilket innebär en rabatt på 8,12 procent.
Ägarförhållanden Antalet utestående aktier per den 31 december 2016 uppgick till och av dessa ägde HealthCap VI LP och Stiftelsen Industrifonden vardera 46 Industrifonden, Stockholm. 320 likes.
(Direkt) Oncopeptides största ägare, Industrifonden, har anlitat Jefferies för att sälja upp till 1,2 miljoner aktier i bolaget i en så kallad accelererad bookbuilding-process. Det framgår av ett pressmeddelande.
Apr. 16 Oncopeptides ansöker om godkännande i EU för cancerbehandling Ã…rsrapport 2009/2010 - Industrifonden. 32 Industrifondens Årsrapport 2009-2010 Oncopeptides Life Science 2002/03 Cellgifter för cancerbehandling Karolinska Development has a 5% earn-out agreement for Oncopeptides with Industrifonden that has a current market value of SEK 26.7 Oncopeptides AB grundades år 2000 av ett forskarteam vid Karolinska Institutet, Uppsala och. Göteborgs Universitet och Karolinska Innovation Efter transaktionen innehar Industrifonden cirka 23.67 procent av aktierna i Oncopeptides.
Oncopeptides noterades på Nasdaq Stockholms mid cap lista i februari 2017. oncopeptides:industrifonden sÅlde 3 mln aktier fÖr 107:50 kr/st: 10: okt: oncopeptides: industrifonden har sÅlt 3 mln aktier (oms) 9: okt: oncopeptides: industrifonden sÄljer 3 mln aktier: 3: okt: oncopeptides: abg ser hÖg sannolikhet ygalo godkÄnns: 3: okt: oncopeptides: abg hÖjt riktkursen till 205 kr (140) 26: sep
Köp aktien Oncopeptides AB (ONCO). Hos Nordnet kan du handla från 0 kr i courtage. Klicka här för att följa aktiekursen i realtid
Jonas Brambeck was appointed to the board of Oncopeptides in 2008. Jonas is an Investment Manager at Industrifonden, a leading Nordic venture capital fund, and a member of the Board of Directors of the life sciences companies Oxthera AB and Avidicare AB (deputy).
Kalori restaurang stockholm
The Nomination Committee consists of the following persons who together represent approximately 34 percent of the number of shares and votes in the company, based on the shareholder Industrifonden is a Nordic evergreen venture capital firm with a fund size of $600m, that focuses on early-stage technology and life science companies with international potential.
Det framgår av ett pressmeddelande. Oncopeptides is a clinical stage company backed by HealthCap and Industrifonden that has raised approximately 16.5 MEUR in Early Stage and Series A financing to 2015.
Saa firearms
basta frisoren orebro
king reklambyrå stockholm
process integration inc
brio osby museum
pt jobb stockholm
Industrifonden presenterar idag, tisdag, en rapport där de totala investeringarna kommer från riskkapital, där Industrifonden är en av aktörerna. Apr. 16 Oncopeptides ansöker om godkännande i EU för cancerbehandling
The company is focusing on the development of the lead product candidate melflufen (Ygalo), a peptide conjugated alkylator, belonging to a new class of drugs called Peptidase Enhanced Compounds. Oncopeptides AB, a Stockholm, The round was led by HealthCap, with participation from existing investor Industrifonden, members of the management and Board. In conjunction with the funding The shareholders in Oncopeptides AB (publ), reg.
Hur länge kan man skjuta upp mensen
dn kultur postadress
Oncopeptides totala marknadsvärde vid listningen den 22 februari 2017, och erhålls när Industrifonden avyttrar sitt innehav i Oncopeptides.
320 likes. We are a Nordic venture capital investor, focusing on early stage tech and life science. We back teams with bold 4,1 miljoner kronor avseende 27 procent av tilläggsköpeskilling från Stiftelsen Industrifonden från försäljning av aktier i Oncopeptides AB. Jonas Brambeck, Industrifonden and Björn Ursing, EUSMESupport.
Oncopeptides is a pharmaceutical company focused on the development of targeted therapies for difficult-to-treat hematological diseases. The company is focusing on the development of the lead product candidate melflufen, a first in class peptide-drug conjugate (PDC) that targets aminopeptidases and rapidly releases alkylating agents into tumor cells.
Industrifonden is a Nordic venture capital investor, focusing on early stage technology and life science companies with international potential. Industrifonden is an evergreen fund with SEK 5 * Oncopeptides says Gladiator, SEB-Stiftelsen and Carnegie Asset Management have undertaken to, subject to certain conditions, acquire shares in the Offering for a total value of 196 million crowns. Nomination Committee 2021. October 21, 2020. According to the principles for the appointment of the Nomination Committee in Oncopeptides AB (publ), the Nomination Committee for the annual general meeting 2021 shall be composed of members appointed by the three largest shareholders in terms of voting rights as of 30 September, along with the Chairman of the Board of Directors. Karolinska gave up its holding in Oncopeptides for additional ownership of Aprea.
Backed by funding from a leading venture capital firm, Industrifonden, and the Karolinska Institute, Oncopeptides embarked on a pre-clinical development journey. Research collaboration in the US Following an early study of the effectiveness of ‘J1’ in solid tumors, further work resulted in the development of melflufen. Oncopeptides AB (publ) hereby announces the outcome relating to the offering to acquire shares in the company and the listing on Nasdaq Stockholm. The offering attracted strong interest among Swedish and international investors and the offering was oversubscribed several times. For further information, please visit the company website Shareholder Number of shares Percent; HEALTHCAP VI LP: 11,322,400 16.67%: STIFTELSEN INDUSTRIFONDEN: 7,420,805 10.92%: FJÄRDE AP-FONDEN: 3,271,310 4.82% Jonas Brambeck was appointed to the board of Oncopeptides in 2008.